Annual Reports in Medicinal Chemistry: Annual Reports in Medicinal Chemistry, cartea 48
Manoj C Desaien Limba Engleză Paperback – 10 noi 2013
- Annual Reports in Medicinal Chemistry provides timely and critical reviews and this volume covers important topics such as drug Discovery, Idiopathic Pulmonary Fibrosis and Neuraminidase Inhibitors
Din seria Annual Reports in Medicinal Chemistry
- 26% Preț: 831.75 lei
- 27% Preț: 945.83 lei
- 27% Preț: 993.51 lei
- 27% Preț: 992.59 lei
- 32% Preț: 726.43 lei
- 32% Preț: 809.18 lei
- 30% Preț: 829.48 lei
- 30% Preț: 828.15 lei
- 30% Preț: 829.23 lei
- 30% Preț: 831.99 lei
- 33% Preț: 796.01 lei
- 29% Preț: 790.27 lei
- 29% Preț: 789.26 lei
- 26% Preț: 830.12 lei
- 5% Preț: 830.12 lei
- 26% Preț: 827.67 lei
- 26% Preț: 828.61 lei
- 26% Preț: 828.63 lei
Preț: 609.12 lei
Preț vechi: 896.02 lei
-32% Nou
Puncte Express: 914
Preț estimativ în valută:
116.61€ • 126.62$ • 98.07£
116.61€ • 126.62$ • 98.07£
Carte tipărită la comandă
Livrare economică 09-23 decembrie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780124171503
ISBN-10: 0124171508
Pagini: 672
Ilustrații: black & white tables, figures, colour plates
Dimensiuni: 152 x 229 x 25 mm
Greutate: 0.86 kg
Editura: ELSEVIER SCIENCE
Seria Annual Reports in Medicinal Chemistry
ISBN-10: 0124171508
Pagini: 672
Ilustrații: black & white tables, figures, colour plates
Dimensiuni: 152 x 229 x 25 mm
Greutate: 0.86 kg
Editura: ELSEVIER SCIENCE
Seria Annual Reports in Medicinal Chemistry
Public țintă
medicinal, pharmaceutical, and organic chemistsCuprins
- Challenges in Drug Discovery at Schering-Plough Research Institute: A Personal Reflection
- My Perspective on Time, Managers—and Scientific Fun
- A Career in Medicinal Chemistry - A Journey in Drug Discovery
- Selective Inhibitors of PDE2, PDE9 and PDE10 - Modulators of Activity of the Central Nervous System
- Beyond Secretases: Kinases Inhibitors for the Treatment of Alzheimer’s Disease
- Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders
- Discovery and Development of Prolylcarboxypeptidase (PRCP) Inhibitors for Cardiometabolic Disorders
- Molecular Targeting of Imaging and Drug Delivery Probes in Atherosclerosis
- Oral GLP-1 Modulators for the Treatment of Diabetes
- Recent Advances in the Discovery and Development of CCR1 Antagonists
- Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis
- Targeting the Nuclear Hormone Receptor RORgt for the Treatment of Autoimmune and Inflammatory Disorders
- Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase- and Bromodomain Inhibitors
- Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy
- Targeting Protein–Protein Interactions to Treat Cancer?Recent Progress and Future Directions
- Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-influenza Agents
- Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection
- Special Challenges to the Rational Design of Antibacterial Agents
- Recent Advances in Small Molecule Target Identification Methods
- Neuroinflammation in Mood Disorders: Mechanisms and Drug Targets
- Inhibitors of hERG Channel Trafficking—A Cryptic Mechanism For QT Prolongation
- Recent Progress in Small-Molecule Agents Against Age-Related Macular Degeneration
- Synthetic Macrocycles in Small-Molecule Drug Discovery
- Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2011)
- Case History: XalkoriTM (Crizotinib), a Potent and Selective Dual Inhibitor of MET and ALK for Cancer Treatment
- Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma
- New Chemical Entities Entering Phase III Trials in 2012 28. To Market, to Market—2012
Recenzii
"This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." --Enzymeologia